16 Updates, Four New Recommendations Issued for Management of Pediatric VTE
By Elana Gotkine HealthDay Reporter
FRIDAY, May 30, 2025 -- In clinical guidelines issued by the American Society of Hematology and the International Society on Thrombosis and Haemostasis, and published online May 27 in Blood Advances, new and updated recommendations are presented for the treatment of pediatric venous thromboembolism (VTE).
Paul Monagle, M.D., M.B.B.S., from the University of Melbourne in Australia, and colleagues developed evidence-based guidelines to support patients, clinicians, and other health care professionals in decisions regarding management of pediatric patients with VTE.
The authors updated 16 recommendations and added four new recommendations. These include suggested use of anticoagulation rather than no anticoagulation for pediatric patients with symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE) (conditional recommendation). Use of anticoagulation or no anticoagulation is suggested for pediatric patients with clinically unsuspected (asymptomatic) DVT or PE (conditional recommendation). Six weeks of anticoagulation is suggested rather than three months for select pediatric patients with provoked VTE (conditional recommendation). Anticoagulation is suggested for six to 12 months rather than indefinitely for pediatric patients with unprovoked DVT or PE (conditional recommendation). Direct oral anticoagulants (rivaroxaban/dabigatran) are suggested over standard of care anticoagulants (low molecular weight heparin, unfractionated heparin, vitamin K antagonist, or fondaparinux) for pediatric patients with VTE (conditional recommendation). Use of either rivaroxaban or dabigatran is suggested for pediatric patients with VTE, with individual populations or jurisdictional availability leading clinicians to choose one over the other.
"The care of children is important, and parents should know that there is a body of evidence that supports their child's treatment options," Monagle said in a statement.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Risk for Death From Prostate Cancer Low With Guideline Care for Nonmetastatic Disease
MONDAY, July 14, 2025 -- Men with nonmetastatic prostate cancer receiving guideline-concordant care have a much higher risk for death from causes other than prostate cancer...
AI Support Improves Breast Cancer Detection Accuracy in Mammography
MONDAY, July 14, 2025 -- Artificial intelligence (AI) support improves radiologists' breast cancer detection accuracy when reading mammograms, according to a study published...
Consistent Physical Activity Linked to Reduced All-Cause, CVD Mortality
FRIDAY, July 11, 2025 -- Consistently and increasingly accumulated physical activity (PA) is associated with a reduced risk for all-cause and cardiovascular disease (CVD)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.